Pharma major Lupin Limited has announced a strategic collaboration with LABORATORIOS ERN S.A. for the launch of Luforbec (beclometasone/formoterol) 100/6 in Spain. 

The product is a fixed-dose combination therapy delivered through a pressurized metered-dose inhaler (pMDI) and is indicated for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD).

Luforbec combines beclometasone dipropionate, an inhaled corticosteroid, with formoterol fumarate, a long-acting bronchodilator, providing a treatment option for patients requiring maintenance therapy for asthma and COPD.

Thierry Volle, President EMEA and Emerging Markets, Lupin, said: “The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care.”

The launch follows the successful introduction of Luforbec® in other key European markets, including the United Kingdom and Germany, further strengthening Lupin’s respiratory franchise across the region.

David Solanes, Chief Executive Officer of LABORATORIOS ERN, said, “Partnering with Lupin allows us to bring a proven, high-value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area.”